Department of Biochemistry & Molecular Pharmacology

The Department of Biochemistry and Molecular Pharmacology at NYU Langone Health has a rich and distinguished history and maintains active research programs in epigenetics, genome integrity, protein degradation, cell cycle control, drug design, and cancer biology.
Research interests in the department include single-molecule and crystallographic investigations of protein macromolecules, analysis of the molecular basis of cell division, and the elucidation of the cellular signaling pathways involved in growth control and DNA repair. In the following videos, faculty members in the Department of Biochemistry and Molecular Pharmacology highlight the innovative research taking place in their labs.
Our faculty have received an average of $22.5 million in funding each year for the past 5 years. This funding comes from an array of federal and private sources, including the National Institutes of Health, the Howard Hughes Medical Institute, the American Cancer Society, the U.S. Department of Defense, and the New York State Department of Health.
We invite you to learn more about our faculty, educational programs, and events.
A Noncanonical Function of SKP1 Regulates the Switch Between Autophagy and Unconventional Secretion
Read More
Structural Basis of Histone H2A Lysine 119 Deubiquitination by Polycomb Repressive Deubiquitinase BAP1/ASXL1
Read More
Spermatogonial Dedifferentiation into Germline Stem Cells in Drosophila Testes
Read More
Faculty

Education

Events

Related News

Clinical Trial Tests Aquablation Therapy for Prostate Cancer

Researchers Assemble Nine Synthetic Yeast Chromosomes

Mice Survive COVID as Humans Do

Bacterial Mutants Suggest Way to Increase Antibiotic Potency

Researchers Reveal Newfound DNA Repair Mechanism

Surprising Insights into the Role of Oxygen in Cancer Cells

New AI Tool Makes Speedy Gene Editing Possible

Study Shows How Many Americans Have VEXAS Syndrome

Grant Supports Early Melanoma Metastasis Research

New Method Kills Cancer Cells Resistant to a KRAS Inhibitor

New Technology Overcomes Limits of Two Major Drug Classes
